We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Hybrids Enters Agreement With Microgen

By Labmedica staff writers
Posted on 26 Jan 2007
Diagnostic Hybrids Inc. More...
(DHI, Athens, OH, USA) has announced that the company signed a product distribution agreement with Microgen Bioproducts Limited (Camberley, UK) a technology-based diagnostics company. Microgen will be responsible for sales and representation of DHI virology products in Wales, Scotland, Ireland, and England. The distribution agreement is effective immediately and will focus initially on introducing specific respiratory virus detection products in the United Kingdom. This agreement extends the exposure of DHI virology products to a population of 60 million people.

Microgen Bioproducts is an independent, private company that is engaged in the development, manufacture and sale of products used by laboratory professionals to aid in the detection and diagnosis of diseases and organisms which pose a threat to human and animal health. The company supplies infectious disease and food pathogen detection tests. Microgen has expertise and experience in the creation and manufacture of diagnostic tests for enteric pathogens and infectious diseases. They operate a direct sales force in the United Kingdom.

Diagnostic Hybrids is a bioscience firm that develops, manufactures, and markets innovative cell culture products for multiple applications in diagnostic virology and endocrine disease. These products offer laboratory staff a rapid, cost-effective diagnostic solution to an otherwise lengthy and expensive process. They currently sell their products to over 600 customers domestically and throughout North America.

Daniel Deery, Ph.D., managing director of Microgen, predicts that DHI's products will do well in the UK. "Sensitive and innovative tissue cell cultures are becoming difficult for customers in the UK to access locally” explained Dr. Deery, "especially with traditional sources of these cells in the UK closing. We believe DHI's cell culture products are the most sensitive and reliable commercial-grade cell cultures in the world and we are committed to providing our customers immediate access to these products cost-effectively.”

DHI has recently completed preparations for CE Marking of specific products intended for sale in the UK and other countries of Europe. This will allow DHI to freely circulate its products within the European marketplace. In addition, DHI has developed a quality management system that is in compliance with the international standard for medical devices, ISO 13485.



Related Links:
Diagnostic Hybrids
Microgen Bioproducts

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.